Advanced mechanisms in drug delivery

Advanced mechanisms in drug delivery

Impact and assessment of modern mechanisms in drug delivery systems

Research Code: D6A0-01-00-00-00
SKU: LS00001-GL-TR_16842


Special Price $3,712.50 save 25 %

In stock


$3,712.50 save 25 %


Pay by invoice



Drug delivery refers to the efficient transport of an active pharmaceutical compound to provide a therapeutic effect that is required by the human body. Drug delivery systems are extremely crucial for patients who require regular doses of medication through the prescribed route of administration. The research study deals with drug delivery mechanisms that are categorized as existing and emerging carriers or technologies that deliver the therapeutic at the target site. Drug delivery industry has witnessed a sea change as majority of the conventional carriers such as polymeric micelles, dendrimers and niosomes are being slowly replaced by emerging approaches such as cyclodextrins, microemulsions, hydrogels, etc. due to their ability to improve drug solubility and bioavailability which help the drug cope with the hostile nature of the gastro-intestinal tract. The research study covers the stakeholder analysis of the key players in the drug delivery industry, particularly the drug delivery technology developers and pharmaceutical manufacturers and also assesses the technology adoption with respect to these mechanisms. Finally, opportunity evaluation has been conducted to understand the scope of future mechanisms in drug delivery with the help of a technology roadmap, partnerships model that assess the partnerships based on technology licensing, product development and distribution and the IP landscape that evaluate the level of interest of existing and emerging technologies amongst key stakeholders.

Table of Contents

Research Process Methodology

Research Methodology (continued)

Key Findings

Technology Roadmap

Polymeric Micelles

Polymeric Micelles


Phosphorous Acids

Starch-Based Carrier

Starch-Based Carrier (continued)


Liposomes (continued)


Microemulsions (continued)

Magnetic Nanoparticles (MNPs)/ Mesoporous silica systems (MSPs)

Magnetic Nanoparticles (MNPs)

Biodegradable Microstructure Patch Technology

Biodegradable Microstructure Patch Technology (continued)


Cyclodextrins (continued)

Functional Micelles/Biomimetic Microvesicles/Nanosomes

Functional Micelles/Biomimetic Microvesicles/Nanosomes (continued)

Functional Micelles/Biomimetic Microvesicles/NanosomesRecent Innovations (continued)

Supramolecular Architectures

Supramolecular Architectures

Microencapsulated Phase Change Materials

Microencapsulated Phase Change Materials (continued)

Fluid Crystal Nanoparticles/Cholesteric Liquid Crystal/Liquid Crystalline Dendrimers

Fluid Crystal Nanoparticles

Technology Landscape

Demand side Analysis

Stakeholder Analysis

Stakeholder Analysis (continued)

Stakeholder analysis (continued)

SWOT analysis of Key Participants

Funding Assessment

Funding Assessment (continued)

Emerging Technology Roadmap

Emerging Technology Roadmap (continued)

Assessment of Partnerships

Assessment of Partnerships (continued)

Assessment of Partnerships (continued)

Assessment of Partnerships (continued)

Assessment of Partnerships (continued)

Assessment of Partnerships (continued)

Technology Management Strategies

Patent scenario

Patent scenario (continued)

Key contacts

Global Patents

Global Patents (continued)

Legal Disclaimer

The Frost & Sullivan Story

Value Proposition: Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The research service aims to give a global outlook of the companion diagnostic market landscape, with a specific focus on Western European countries. The segments related to oncology discussed in this study include breast cancer, lung cancer, colorectal cancer and other cancers, and non-oncology related infectious disease, CNS, and cardiovascular. The forecasts are based on test volumes for these cancers and disease types. Effective analysis of the reimbursement pathway in Germany, the United Kingdom, France, Italy, Spain, Scandinavia, and Benelux, coupled with regulatory approval in Europe, is discussed. A comparative assessment of regulatory scenarios has been performed to assess easy-target markets.
More Information
No Index No
Podcast No
Author Karan Verma
WIP Number D6A0-01-00-00-00
Is Prebook No